Dr. Caldwell has 25+ years of experience in biomedical research, drug/drug target discovery, advancing disruptive biotechnologies, platform development and integration, advanced development, and regulatory affairs spanning the biotech industry, academic institutions, and government agencies.
Rob’s technical proficiencies include multi-omics discovery approaches, BSL3/4 laboratory experimentation, data management and interpretation, in silico chemistry, population genetics, and integrating and optimizing AI/ML tools for drug:target interaction. He is a subject matter expert across neuropathology (e.g., chemical dependencies), infectious diseases, and tissue regeneration and wound healing.
Rob is a seasoned advisor and published expert on all aspects of product development and R&D of medical countermeasures. He regularly helps life sciences companies identify opportunities for government funding for the development of medical countermeasures, prepare white papers/abstracts/proposals to request funding, negotiate awards, and successfully manage the resulting contracts or grants.
Rob has also provided advisory services directly to the highest levels of government agencies within the Pentagon R&D enterprise, including the JPEO, DTRA JSTO, DTRA CTR, and DARPA, as well as public health agencies (e.g., NIH, BARDA, ARPA-H).